Eli Lilly and Co (XSWX:LLY) Cash Flow from Investing: CHF-19,997 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:LLY Eli Lilly and Co XSWX:LLY
92 GF Score
Price CHF980.00
GF Value CHF1,238.28
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Eli Lilly and Co Cash Flow from Investing?

Eli Lilly and Co XSWX:LLY -2.00% 92 Cash Flow from Investing is CHF-19,997 Mil as of Jun. 2026. GuruFocus rates XSWX:LLY with a GF Score™ of 92/100 and a GF Value™ of CHF1,238.28 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Jun. 2026, Eli Lilly and Co spent CHF2,344 Mil on purchasing property, plant, equipment. It gained CHF0 Mil from selling property, plant, and equipment. It spent CHF6,991 Mil on purchasing business. It gained CHF0 Mil from selling business. It spent CHF245 Mil on purchasing investments. It gained CHF0 Mil from selling investments. It paid CHF2,623Mil for net Intangibles purchase and sale. And it paid CHF102 Mil for other investing activities. In all, Eli Lilly and Co spent CHF12,306 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Jun. 2026.


Eli Lilly and Co  (XSWX:LLY) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Eli Lilly and Co's purchase of property, plant, equipment for the three months ended in Jun. 2026 was CHF-2,344 Mil. It means Eli Lilly and Co spent CHF2,344 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Eli Lilly and Co's sale of property, plant, equipment for the three months ended in Jun. 2026 was CHF0 Mil. It means Eli Lilly and Co gained CHF0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Eli Lilly and Co's purchase of business for the three months ended in Jun. 2026 was CHF-6,991 Mil. It means Eli Lilly and Co spent CHF6,991 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Eli Lilly and Co's sale of business for the three months ended in Jun. 2026 was CHF0 Mil. It means Eli Lilly and Co gained CHF0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Eli Lilly and Co's purchase of investment for the three months ended in Jun. 2026 was CHF-245 Mil. It means Eli Lilly and Co spent {stock_data.stock.currency_symbol}}245 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Eli Lilly and Co's sale of investment for the three months ended in Jun. 2026 was CHF0 Mil. It means Eli Lilly and Co gained CHF0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Eli Lilly and Co's net Intangibles purchase and sale for the three months ended in Jun. 2026 was CHF-2,623 Mil. It means Eli Lilly and Co paid CHF2,623 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Eli Lilly and Co's cash from discontinued investing activities for the three months ended in Jun. 2026 was 0 Mil. It means Eli Lilly and Co paid CHF0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Eli Lilly and Co's cash from other investing activities for the three months ended in Jun. 2026 was CHF-102 Mil. It means Eli Lilly and Co paid CHF102 Mil for other investing activities.


Eli Lilly and Co Cash Flow from Investing Related Terms


Eli Lilly and Co Cash Flow from Investing Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Cash Flow from Investing Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,640.97 -3,505.52 -6,185.91 -8,293.66 -8,743.59

Eli Lilly and Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,491.41 -2,374.61 -2,233.07 -3,083.07 -12,306.02
XSWX:LLY
92GF Score
Eli Lilly and Co XSWX:LLY
Cash Flow from Investing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Eli Lilly and Co's Cash Flow from Investing for the fiscal year that ended in Dec. 2025 is calculated as:

Eli Lilly and Co's Cash Flow from Investing for the quarter that ended in Jun. 2026 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-19,997 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Investing of CHF-19,997 Mil mean?
Eli Lilly and Co (XSWX:LLY) has a Cash Flow from Investing of CHF-19,997 Mil as of Jun. 2026. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's Cash Flow from Investing too high?
Eli Lilly and Co's current Cash Flow from Investing is CHF-19,997 Mil. Overall, Eli Lilly and Co has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Cash Flow from Investing compare to JNJ and ABBV?
Eli Lilly and Co's Cash Flow from Investing of CHF-19,997 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Investing for a Drug Manufacturers company?
A good Cash Flow from Investing depends on the Drug Manufacturers industry context. However, Cash Flow from Investing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Investing mean?
A high Cash Flow from Investing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Eli Lilly and Co and its competitors. Eli Lilly and Co's current Cash Flow from Investing is CHF-19,997 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,238.28, compared to a current price of CHF980.00 — trading 20.9% below its estimated fair value. The current Cash Flow from Investing is CHF-19,997 Mil. Eli Lilly and Co's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Investing calculated?
Cash Flow from Investing is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Cash Flow from Investing is CHF-19,997 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of CHF980.00 is trading 20.9% below its estimated GF Value™ of CHF1,238.28. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for XSWX:LLY:

  • Cash Flow from Investing: CHF-19,997 Mil
  • GF Value™: CHF1,238.28 vs. price of CHF980.00 (20.9% below fair value)
  • GF Score™: 92/100 with 4 warning signs

No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
92GF Score

Get the complete analysis for XSWX:LLY

Cash Flow from Investing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF980.00
Price
CHF1,238.28
GF Value